Back to Directory Camlin Tierney Email tierney@sdac.harvard.edu Institution Statistical and Data Analysis Center Title Research Scientist Request an Update Affiliated Studies IMPAACT 2052: Safety and pharmacokinetics of an AAV-Vectored broadly neutralizing antibody in infants living with HIV DAIDS Number 39268 Research Area Cure and Immunotherapy Study Status In Development P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2039A: Phase I Study of the Safety and Immunogenicity of HIVconsvX Vaccines and the Safety and Pharmacokinetics of Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number 39194 Research Area Cure and Immunotherapy Study Status In Development IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Open to Accrual Show All
IMPAACT 2052: Safety and pharmacokinetics of an AAV-Vectored broadly neutralizing antibody in infants living with HIV DAIDS Number 39268 Research Area Cure and Immunotherapy Study Status In Development
P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2039A: Phase I Study of the Safety and Immunogenicity of HIVconsvX Vaccines and the Safety and Pharmacokinetics of Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number 39194 Research Area Cure and Immunotherapy Study Status In Development
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Open to Accrual
